Metastatic breast cancer endpoints for survival: rwPFS and TTNT
Dr Christopher Labaki speaks to ecancer about real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT). Those are the two endpoints of clinical interest in patients with metastatic breast cancer (MBC). Their validation as intermediate endpoints for overall survival (OS), in a real-world setting, remains not fully established.
Dr Labaki and his team conducted a cohort study of pts diagnosed with MBC from Jan 1, 2011 through Feb 30, 2021.
Kendall’s tau was calculated in the full cohort, and within each subgroup of metastatic disease, as defined by the occurrence of bone metastases (mets) only (subgroup 1), non-hepatic visceral mets +/- bone mets (subgroup 2), liver mets +/- other visceral and/or bone mets (subgroup 3), and one or more brain mets +/- other types of metastasis (subgroup 4).
The results concluded that rwPFS and TTNT may represent meaningful intermediate endpoints for OS in patients with MBC overall and within different disease subgroups.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
No comments found